Overview

Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and progression-free survival in CLL patients
Phase:
Phase 2
Details
Lead Sponsor:
John Byrd
Ohio State University Comprehensive Cancer Center
Collaborators:
Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.
Treatments:
Cyclophosphamide
Pentostatin
Rituximab